Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06709820 | A Study of LY4060874 in Healthy Participants | PHASE1 | COMPLETED | 121 | — | — | Dec 2, 2024 | Feb 20, 2026 | Apr 3, 2026 | 2 | United States, Singapore |
Number of participants with one or more TEAEs and SAEs.
| Arm | Type | Description |
|---|---|---|
| LY4060874 (Part A Subcutaneous) | EXPERIMENTAL | Single ascending dose of LY4060874 administered subcutaneously (SC). |
| LY4060874 (Part A Intravenous) | EXPERIMENTAL | Single ascending dose of LY4060874 administered intravenously (IV). |
| LY4060874 (Part B) | EXPERIMENTAL | Multiple ascending doses of LY4060874 administered SC. |
| LY4060874 (Part B Chinese) | EXPERIMENTAL | Multiple ascending doses of LY4060874 administered SC in Chinese participants. |
| LY4060874 (Part C Japanese) | EXPERIMENTAL | Multiple ascending doses of LY4060874 administered SC in Japanese participants. |
| Placebo (SC) | PLACEBO_COMPARATOR | Placebo administered SC in Part A, B, and C. |
| Placebo (IV) | PLACEBO_COMPARATOR | Placebo administered IV in Part A. |
| Name | Type | Description |
|---|---|---|
| LY4060874 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Are overtly healthy as determined by medical evaluation, including medical history and physical examination. * Have a body mass index in the range of 20 to 29.9 kilogram per meter squared (kg/m²), inclusive, at screening. * To qualify as Chinese for this study, all 4 of the pa...